Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-12-11
2007-12-11
Rawlings, Stephen L. (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007920, C436S064000, C436S501000, C530S350000, C530S387700, C530S389700
Reexamination Certificate
active
10650057
ABSTRACT:
The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a solubilized body sample. The present invention is particularly directed to a method for detecting cervical carcinomas, cervical intraepithelial neoplasias, or cervical carcinomas in-situ from a solubilized cervical body sample of a human subject, by solubilizing the cervical body sample in a lysis buffer, and determining the overexpression of cyclin dependent kinase inhibitor p16 in the solubilized cervical sample. The invention also concerns a test kit usable for this purpose as well as an in-vitro diagnostic device.
REFERENCES:
patent: 4281061 (1981-07-01), Zuk et al.
patent: 5889169 (1999-03-01), Beach et al.
patent: 6033847 (2000-03-01), Sherr et al.
patent: 6316208 (2001-11-01), Roberts et al.
patent: 6403383 (2002-06-01), Casterlin et al.
patent: 6709832 (2004-03-01), Von Knebel Doeberitz et al.
patent: 2001/0039023 (2001-11-01), Schubert
patent: 2002/0086288 (2002-07-01), Bird et al.
patent: 2003/0157482 (2003-08-01), Keesee et al.
patent: 0 723 156 (1995-12-01), None
patent: 1 217 377 (2001-12-01), None
patent: WO/9220796 (1992-11-01), None
patent: WO 99/04238 (1998-07-01), None
Geradts et al. (Am. J. Pathol. Jun. 1999; 154 (6): 1665-1671).
Ryder et al. (Clin. Chem. Dec. 1988 34 (12): 2513-2516).
Khleif et al. (Proc. Natl. Acad. Sci. USA. Apr. 1996 93: 4350-4354).
Sano et al. (Pathology International. 1998; 48: 580-585).
Ikeda et al. (J. Histochem. Cytochem. 1998; 46 (3): 397-403).
Wentzensen et al. Cancer. 2006; 107: 2307-13.
Mao et al. Int. J. Cancer. 2007; 120: 2435-8.
Suneja et al. Brain Res. Protocols. 1998; 3: 88-93.
Castellano et al. Cancer Res. Nov. 1, 1997; 57: 4868-75.
Plath et al. J. Cell Biol. Sep. 18, 2000; 150 (6): 1467-77.
Gump et al. J. Biol. Chem. Feb. 28, 2003; 278 (9): 6619-22.
Dai et al. Gastroenterology. 2000; 119: 929-42.
Qualtiere et al. (J. Immunol. Nov. 1977; 119(5): 1645-1651).
Dimitriadis et al. (Anal. Biochem. Oct. 1, 1979; 98 (2): 445-451).
McCabe et al. (J. Immunol. Methods. Apr. 6, 1988; 108 (1-2): 129-135).
Bhakdi (J. Biochem. Biophys. Methods. Jan.-Feb. 2, 1980; 2 (1): 79-90).
Liggett et al. (J. Clin. Oncol. Mar. 1998;16 (3): 1197-1206).
Geradts, et al., “Immunohistochemical Detection of the Cyclin-dependent Kinase Inhibitor 2/Multiple Tumor Suppressor Gene 1 (CDKN2/MTS1) Productp16INK4Ain Archival Human Solid Tumors: Correlation with Retinoblastoma Protein Expression”,Cancer Research55: 6006-11 (1995).
Hirama, et al., “p16 (CDKN2/Cylin-dependent Kinase-+inhibitor/Multiple Tumor Suppressor-1) Gene Is Not Altered in Uterine Cervical Carcinomas or Cell Lines”,Modern Pathology, 9(1) 26-31 (1996).
Kelley, et al., “CDKN2 in HPV-Positive and HPV-Negative Cervical-Carcinoma Cell Lines”,Int. J. Cancer, 63: 226-30 (1995).
Kim, et al., “Absence ofp15INK4Bandp16INK4AGene Alterations in Primary Cervical Carcinoma Tissues and Cell Lines with Human Papillomavirus Infection”,Gynecologic Oncology, 70: 75-9 (1998).
Kim, et al., “Underexpression of Cyclin-Dependent Kinase (CDK) Inhibitors in Cervical Carcinoma”,Gynecologic Oncology, 71: 38-45 (1998).
Klaes, et al., “Overexpression ofp16INK4Aas a Specific Marker for Dysplastic and Neoplastic Epithelial Cells of the Cervix Uteri”,Int. J. Cancer, 92: 276-284 (2001).
Milde-Langosch, et al., “P16/MTS1 andpRB expression in endometrial carcinomas”,Virchows Arch, 434: 23-8 (1999).
Milde-Langosch, et al.,p16/MTS1 Inactivation in Ovarian Carcinomas: High Frequency of rEduced.
Protein expression Associated with Hyper-Methylation or Mutation in Endometroid and Mucinous Tumors ,Int. J. Cancer, 79: 61-5 (1998).
Nuovo, et al., “In situ detection of the hypermethylation-induced inactivation of thep16 gene as a early event in oncogenesis”,PNAS, 96(22): 12754-9 (1999).
Sano, et al., “Expression Status ofp16 Protein Is Associated with Human Papillomavirus Oncogenic Potential in Cervical and Genital Lesions”,American Journal of Pathology, 153(6): 1741-8 (1998).
Sano, et al., “Immunohistochemical overexpression ofp16 protein associated with intact retinoblastoma protein expression in cervical cancer and cervical intraepithelial neoplasia”,Pathology International, 48: 580-5 (1998).
Serrano, et al., “A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4”,Nature, 366: 704-7 (1993).
Shigemasa, et al., “p16 Overexpression: A Potential Early Indicator of Transformation in Ovarian Carcinoma”,J. Soc. Gynecol Invest., 4(2): 95-102 (1997).
Shim, et al., “Profiling of Differentially Expressed Genes in Human Primary Cervical Cancer by Complementary DNA Expression Array”,Clinical Cancer Research, 4: 3045-50 (1998).
Tam, et al., “Differential Expression and Cell Cycle Regulation of the Cyclin-dependent Kinase 4 Inhibitorp16INK4”,Cancer Research, 54: 1816-20 (1994).
Wong, et al., “Methylation ofp16INK4Ain primary gynecologic malignancy”,Cancer Letters, 136: 231-5 (1999).
Wong, et al.,p16INK4andp15INK4BAlterations in Primary Gynecologic Malignancy,Gynecologic Oncology65: 319-24 (1997).
He, et al., “Expression, Deletion And Mutation of p16 Gene in Human Gastric Cancer”World J. of Gastroenterology7(4): 515-521 (2001).
Myung, et al., “Loss Of p16 And p27 Is Associated With Progression Of Human Gastric Cancer”Cancer Letters153:129-136 (2000).
Nakao et al., “Induction of p16 During Immortalization HPV 16 and 18 and Not During Malignant Transformation”British J of Cancer75(10):1410- 1416, 1997.
O'Nions, et al., “p73 Is Over-Expressed In Vulval Cancer Principally As The Δ2 Isoform”British J. Cancer85(10):1551-1556 (Nov. 2001).
Sano, et al., “Overexpression Of p16 And P14ARF Is Associated With Human Papillomavirus Infection In Cervical Squamous Cell Carcinoma And Dysplasia”Pathology Int.52:375-383 (May 2002).
Sherr, “The Ink4a/Arf Network in Tumor Suppression”Nature Reviews Mol. Cell Bio2:731-737, (2001).
Takeuchi, et al., “Altered p16/MTSi/CDKN2 and Cycling D1/PRAD-1 Gene Expression Is Associated With The Prognosis of Squamous Cell Carcinoma of the Esophagus”Clinical Cancer Research3:2229-2236, (1997).
Tsujie, et al., “Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer”Oncology58:126-136 (2000).
Doeberitz Magnus Von Knebel
Herkert Matthias
Reichert Anja
Ridder Rüdiger
Howrey LLP
Kung Viola T.
MTM Laboratories AG
Rawlings Stephen L.
LandOfFree
Method for detecting carcinomas in a solubilized cervical... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for detecting carcinomas in a solubilized cervical..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for detecting carcinomas in a solubilized cervical... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3846257